Literature DB >> 2421014

Intracavernous drug-induced erections in the management of male erectile dysfunction: experience with 100 patients.

A A Sidi, J S Cameron, L M Duffy, P H Lange.   

Abstract

A total of 100 men with organic impotence underwent a trial of intracavernous drug-induced erections with a mixture of papaverine (25 mg./ml.) and phentolamine (0.8 mg./ml.). The response rates, that is functional erections, were 100 per cent in patients with neurogenic impotence, 65.7 per cent in those with vasculogenic impotence, 90 per cent in the undetermined group and 64.7 per cent in the neurogenic/vascular impotence group. Of the responders 79.5 per cent elected to practice self-injection as a method to restore erectile function. The dose required to obtain functional erections in the purely neurogenic impotence group was significantly lower than that required in other groups. Complications were few and included 4 patients with sustained erections that required intervention. Intracavernous injection of vasoactive drugs appears to have promising value in the treatment and differential diagnosis of erectile dysfunction.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421014     DOI: 10.1016/s0022-5347(17)45825-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Prevention of erection after penile surgery. A double-blind trial of intracavernous noradrenaline versus placebo.

Authors:  L V Johansen; H J Kirkeby; J Kiil
Journal:  Urol Res       Date:  1989

2.  Therapeutic roles of intracavernosal papaverine.

Authors:  I Goldstein; T Payton; H Padma-Nathan
Journal:  Cardiovasc Intervent Radiol       Date:  1988-08       Impact factor: 2.740

Review 3.  Self-administration in the pharmacological treatment of impotence.

Authors:  F Bénard; T F Lue
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

4.  Pharmacological priapism: comparison of trazodone- and papaverine-associated cases.

Authors:  E D Bardin; J N Krieger
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

5.  Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate.

Authors:  A Gomaa; M Shalaby; M Osman; M Eissa; A Eizat; M Mahmoud; N Mikhail
Journal:  BMJ       Date:  1996-06-15

Review 6.  Drug-induced male sexual dysfunction. An update.

Authors:  G B Brock; T F Lue
Journal:  Drug Saf       Date:  1993-06       Impact factor: 5.606

7.  Correlation between intracavernous papaverine injection, Doppler analysis and cavernosography in impotent patients.

Authors:  Y S Sargin; H A Ozen; I Başar; A Ergen; I Celebi; D Erol; C Koçal; D Remzi
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

8.  Relaxation of isolated corpus cavernosum induced by smooth-muscle relaxant drugs. A comparative study.

Authors:  G Barbanti; P Beneforti; A Lapini; D Turini
Journal:  Urol Res       Date:  1988

Review 9.  [The impact of spinal cord injury on sexuality and reproduction].

Authors:  A Reitz; H Burgdörfer; B Schurch
Journal:  Urologe A       Date:  2004-01       Impact factor: 0.639

10.  Dose-dependent effect and side-effect of prostaglandin E1 in erectile dysfunction.

Authors:  P Schramek; M Waldhauser
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.